AbbVie's drug met the main goal in a late-stage trial when tested in patients with early Parkinson's disease, the company said on Thursday.Patients showed a statistically significant improvement when two fixed doses of the drug,

AbbVie reported Thursday that its experimental Parkinson’s drug that it got from Cerevel Therapeutics helped alleviate symptoms and improve quality of life in a late-stage study.

AbbVie plans to share results from another phase 3 trial of tavapadon later this year, the pharma said in the release. That trial is testing the drug as a flexible-dose monotherapy.

AbbVie reports positive Phase 3 results for tavapadon, a once-daily treatment for early-stage Parkinson's disease. The drug showed significant improvements in patient symptoms, meeting primary and secondary endpoints.

These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also met its primary endpoint ​ earlier this year. The final trial, TEMPO-2 is testing flexible dose tavapadon, also as a monotherapy, and is expected to read out before the end of the year.

AbbVie (ABBV) said its Phase 3 trial TEMPO-1 for experimental therapy Tavapadon reached main goal in Parkinson's disease. Read more here.

The Phase III TEMPO-1 trial enrolled 529 adults aged between 40 and 80 years, diagnosed with Parkinson’s for less than three years.